Nanjing Leads Biolabs Co., Ltd. Class H (9887) Stock Forecast & Price Target

Compare

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

9887 Analyst Ratings

Moderate Buy

1 Buy

0 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Nanjing

Leads Biolabs Co., Ltd. Class H

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

9887 Stock 12 Month Forecast

Average Price Target

HK$101.90

▲(89.23% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Nanjing Leads Biolabs Co., Ltd. Class H in the last 3 months. The average price target is HK$101.90 with a high forecast of HK$101.90 and a low forecast of HK$101.90. The average price target represents a 89.23% change from the last price of HK$53.85.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"50":"HK$50","63":"HK$63","76":"HK$76","89":"HK$89","102":"HK$102"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":101.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$101.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$101.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$101.90</span>\n  </div></div>","useHTML":true}}],"tickPositions":[50,63,76,89,102],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Sep<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51,54.91538461538462,58.830769230769235,62.746153846153845,66.66153846153847,70.57692307692308,74.49230769230769,78.40769230769232,82.32307692307693,86.23846153846154,90.15384615384616,94.06923076923077,97.98461538461538,{"y":101.9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51,54.91538461538462,58.830769230769235,62.746153846153845,66.66153846153847,70.57692307692308,74.49230769230769,78.40769230769232,82.32307692307693,86.23846153846154,90.15384615384616,94.06923076923077,97.98461538461538,{"y":101.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51,54.91538461538462,58.830769230769235,62.746153846153845,66.66153846153847,70.57692307692308,74.49230769230769,78.40769230769232,82.32307692307693,86.23846153846154,90.15384615384616,94.06923076923077,97.98461538461538,{"y":101.9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":73.3,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":73.3,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":73.3,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":73.3,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":73.3,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":73.3,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":73.3,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":70,"date":1754006400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":66.8,"date":1756684800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":66.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$101.90

Average Price TargetHK$101.90

Lowest Price TargetHK$101.90

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Huafu Securities

Not Ranked

Huafu Securities

HK$101.9

Buy

89.23%

Upside

Reiterated

01/21/26

Huafu Securities Remains a Buy on Nanjing Leads Biolabs Co., Ltd. Class H (9887)

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

HK$94

Buy

74.56%

Upside

Reiterated

12/01/25

Citic Securities Keeps Their Buy Rating on Nanjing Leads Biolabs Co., Ltd. Class H (9887)

Unknown Analyst

Cinda International Research Limited

Not Ranked

Cinda International Research Limited

HK$103.56

Buy

92.31%

Upside

Reiterated

11/02/25

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

HK$59

Hold

9.56%

Upside

Reiterated

10/16/25

Jill Wu

CMB International Securities

HK$80.27

Buy

49.06%

Upside

Initiated

09/03/25

Innovative Pipeline and Promising Drug Candidates Drive Buy Rating for Nanjing Leads Biolabs Co., Ltd.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Huafu Securities

Not Ranked

Huafu Securities

HK$101.9

Buy

89.23%

Upside

Reiterated

01/21/26

Huafu Securities Remains a Buy on Nanjing Leads Biolabs Co., Ltd. Class H (9887)

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

HK$94

Buy

74.56%

Upside

Reiterated

12/01/25

Citic Securities Keeps Their Buy Rating on Nanjing Leads Biolabs Co., Ltd. Class H (9887)

Unknown Analyst

Cinda International Research Limited

Not Ranked

Cinda International Research Limited

HK$103.56

Buy

92.31%

Upside

Reiterated

11/02/25

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

HK$59

Hold

9.56%

Upside

Reiterated

10/16/25

Jill Wu

CMB International Securities

HK$80.27

Buy

49.06%

Upside

Initiated

09/03/25

Innovative Pipeline and Promising Drug Candidates Drive Buy Rating for Nanjing Leads Biolabs Co., Ltd.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nanjing Leads Biolabs Co., Ltd. Class H

3 Months

xxx

Success Rate

0/1 ratings generated profit

Average Return

-14.40%

initiated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -14.40% per trade.

1 Year

Jill WuCMB International Securities

Success Rate

0/1 ratings generated profit

Average Return

-16.60%

initiated a buy rating 6 months ago

Copying Jill Wu's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -16.60% per trade.

2 Years

xxx

Success Rate

0/1 ratings generated profit

Average Return

-16.60%

initiated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -16.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9887 Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 9887 has received 2 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 9887 average Analyst price target in the past 3 months is 101.90.

Each month's total comprises the sum of three months' worth of ratings.

9887 Financial Forecast

9887 Earnings Forecast

The previous quarter’s earnings for 9887 were -HK$0.95.

No data currently available

9887 Sales Forecast

The previous quarter’s earnings for 9887 were HK$0.00.

9887 Stock Forecast FAQ

What is HK:9887’s average 12-month price target, according to analysts?

Based on analyst ratings, Nanjing Leads Biolabs Co., Ltd. Class H’s 12-month average price target is 101.90.

What is HK:9887’s upside potential, based on the analysts’ average price target?

Nanjing Leads Biolabs Co., Ltd. Class H has 89.23% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Nanjing Leads Biolabs Co., Ltd. Class H a Buy, Sell or Hold?

Nanjing Leads Biolabs Co., Ltd. Class H has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.

What is Nanjing Leads Biolabs Co., Ltd. Class H’s share price target?

The average share price target for Nanjing Leads Biolabs Co., Ltd. Class H is 101.90. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$101.90 ,and the lowest forecast is HK$101.90. The average share price target represents 89.23% Increase from the current price of HK$53.85.

What do analysts say about Nanjing Leads Biolabs Co., Ltd. Class H?

Nanjing Leads Biolabs Co., Ltd. Class H’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Nanjing Leads Biolabs Co., Ltd. Class H?

To buy shares of HK:9887, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Nanjing Leads Biolabs Co., Ltd. Class H (9887) Stock Forecast & Price Target

9887 Analyst Ratings

9887 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nanjing Leads Biolabs Co., Ltd. Class H

9887 Analyst Recommendation Trends

9887 Financial Forecast

9887 Earnings Forecast

9887 Sales Forecast

9887 Stock Forecast FAQ

Detailed List of Analyst Forecasts